FINWIRES · TerminalLIVE
FINWIRES

AeroVironment's Strong Fiscal Q4, Conservative Fiscal 27 Guidance Boost Confidence in Growth Outlook, RBC Says

By

AeroVironment's (AVAV) "strong" fiscal Q4 results and "conservative" fiscal 2027 guidance reinforce confidence in the defense technology company's growth outlook despite budget uncertainty, with solid bookings and higher investment expected to support organic growth, RBC Capital Markets said in a report emailed Tuesday.

AeroVironment reported fiscal Q4 revenue of $642 million, up 31% organically, with a 21.8% adjusted earnings before interest, taxes, depreciation and amortization margin, the report said.

The firm said the company's initial fiscal 2027 guidance appears deliberately conservative, creating the potential for a "beat and raise" performance over the course of the year, adding that strong fiscal Q4 results could improve investor sentiment, although a broader "re-rating" of the shares will depend on "execution" against fiscal 2027 targets.

Investors are likely to focus on AeroVironment's July 8 Investor Day for updates on its medium-term strategy, according to the report.

RBC maintained an outperform rating on AeroVironment but lowered its price target to $210 from $250.

Price: $158.24, Change: $+19.24, Percent Change: +13.84%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC